Profile data is unavailable for this security.
About the company
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
- Revenue in USD (TTM)0.00
- Net income in USD-12.36m
- Incorporated2020
- Employees3.00
- LocationMira Pharmaceuticals Inc1200 Brickell Avenue, Suite 1950 #1183MIAMI 33131United StatesUSA
- Phone+1 (813) 369-5150
- Websitehttps://mirapharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 9.13m | 14.00 | -- | 9.15 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Notable Labs Ltd | 310.00k | -11.26m | 9.20m | 16.00 | -- | 0.6086 | -- | 29.67 | -3.08 | -3.08 | 0.0939 | 1.68 | 0.0126 | -- | -- | 19,375.00 | -45.79 | -52.02 | -56.70 | -62.09 | 36.45 | 60.19 | -3,633.55 | -3,636.93 | -- | -- | 0.0221 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 9.38m | 20.00 | -- | -- | -- | 721.49 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Molecular Templates Inc | 31.76m | -18.40m | 9.55m | 62.00 | -- | 1.33 | -- | 0.3006 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Weed Inc | 0.00 | -31.55k | 9.63m | 2.00 | -- | 37.73 | 337.48 | -- | -0.0002 | -0.0002 | 0.00 | 0.0021 | 0.00 | -- | -- | 0.00 | -2.49 | -385.93 | -14.84 | -822.37 | -- | -- | -- | -- | -- | -16.98 | 0.3488 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 9.68m | 3.00 | -- | 3.07 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Avalo Therapeutics Inc | 1.45m | -142.88m | 9.92m | 19.00 | -- | -- | -- | 6.84 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Chromocell Therapeutics Corp | 0.00 | -7.38m | 10.09m | 4.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -9,746.19 | -- | -- | -- | -- | -- | -- | -- | -- | -13.23 | -- | -- | -- | -- | -200.20 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 10.14m | 30.00 | -- | 1.05 | -- | 1.04 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 10.26m | -- | -- | 0.1104 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 10.27m | 57.00 | -- | 0.7656 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Oragenics Inc | 37.65k | -20.66m | 10.44m | 5.00 | -- | 4.56 | -- | 277.29 | -8.69 | -8.69 | 0.0167 | 1.03 | 0.0038 | -- | -- | 7,530.00 | -209.44 | -97.60 | -252.98 | -106.24 | -- | -- | -54,862.55 | -36,169.75 | -- | -- | 0.0898 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Data as of May 17 2024. Currency figures normalised to Mira Pharmaceuticals Inc's reporting currency: US Dollar USD
3.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cross Staff Investments, Inc.as of 31 Mar 2024 | 383.40k | 2.59% |
| Suncoast Equity Management LLCas of 31 Mar 2024 | 40.00k | 0.27% |
| HRT Financial LLCas of 31 Mar 2024 | 30.65k | 0.21% |
| Praetorian Wealth Management, Inc.as of 31 Mar 2024 | 27.50k | 0.19% |
| XTX Markets LLCas of 31 Mar 2024 | 25.54k | 0.17% |
| G1 Execution Services LLCas of 31 Mar 2024 | 15.57k | 0.11% |
| Virtu Americas LLCas of 31 Dec 2023 | 14.66k | 0.10% |
| Northern Trust Global Investments Ltd.as of 31 Mar 2024 | 10.23k | 0.07% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 10.23k | 0.07% |
| Cary Street Partners Investment Advisory LLCas of 31 Mar 2024 | 10.00k | 0.07% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
